Development of a Novel Inhibitor of Enterovirus Replication

性状（由申请方提供）：肠道病毒是一种小型无包膜RNA病毒，可引起脊髓灰质炎、脑炎、急性心力衰竭或新生儿重度肝炎以及其他危及生命的感染。在美国，最近爆发的柯萨奇病毒B1（CVB1）感染和柯萨奇病毒A6提醒人们注意这些病原体带来的持续威胁。同样，近20年来，欧洲和亚太地区几乎每年都发生肠道病毒71型的暴发，如果输入，可能导致北美的流行病。我们最近发现了一组新的密切相关的小分子，抑制柯萨奇病毒B（CVB）变异体，脊髓灰质炎病毒和其他肠道病毒的复制。我们提出了一个为期两年的研究，以确定这组化合物的衍生物具有强大的抗病原性肠道病毒的抗病毒活性。这些目标的成功实现可能最终导致抗病毒药物的开发，这些药物可用于危及生命的肠道病毒感染，并可能在根除脊髓灰质炎病毒传播中发挥作用。

DESCRIPTION (provided by applicant): Enteroviruses are small, non-enveloped RNA viruses responsible for poliomyelitis, encephalitis, acute heart failure or severe hepatitis in newborns, and other life threatening infections. In the United States recent outbreaks of coxsackievirus B1 (CVB1) infections and coxsackievirus A6 served as reminders of the ongoing threat raised by these pathogens. Similarly, outbreaks of enterovirus 71 have occurred nearly annually in Europe and the Asia-Pacific region for almost 20 years, and could potentially lead to epidemics in North America if imported. We have recently identified a novel group of closely related small molecules that inhibit the replication of coxsackievirus B (CVB) variants, polioviruses, and other enteroviruses. We propose a two-year study to identify derivatives of this group of compounds with robust antiviral activity against pathogenic enteroviruses. Successful completion of these goals could ultimately lead to the development of antiviral drugs useful in cases of life-threatening enterovirus infections and that could potentially play a role in the eradication of poliovirus circulation.